Crispr Therapeutics' Continued Progress Warrants A Buy

Jul. 25, 2022 4:23 PM ETCRISPR Therapeutics AG (CRSP)JNJ3 Comments
SL Investments profile picture
SL Investments


  • Crispr Therapeutics continues to make progress toward submitting a global regulatory filing for CTX001.
  • CTX130 preliminary data shows the power of Crispr Cas-9 technology.
  • Some valuation risks are present; however, I continue to believe the future opportunity far outweighs the risks seen today.

Genetic manipulation and DNA modification concept.



In my initial coverage of Crispr Therapeutics (NASDAQ:CRSP) in January of 2022, I gave the company a hold rating. At the time, I believed the progress of Crispr Therapeutics did not warrant the company's valuation. Further, the future potential of

This article was written by

SL Investments profile picture
I am a young private investor seeking to find advice and knowledge through my journey in Seeking Alpha. I primarily focus on growth companies and the disruptive future they may bring. Through the rise of technological capabilities, I believe that the world will undergo a massive transition in the coming decade.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.